NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Forecast, Price & News $3.39 +0.04 (+1.19%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$3.29▼$3.4650-Day Range$2.96▼$3.7052-Week Range$2.85▼$13.23Volume1.45 million shsAverage Volume559,345 shsMarket Capitalization$166.33 millionP/E RatioN/ADividend YieldN/APrice Target$9.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media C4 Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside190.8% Upside$9.86 Price TargetShort InterestBearish7.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.91) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector798th out of 1,006 stocksBiological Products, Except Diagnostic Industry127th out of 167 stocks 3.0 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.86, C4 Therapeutics has a forecasted upside of 190.8% from its current price of $3.39.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.24% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 0.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 2.4 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for C4 Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.17% of the stock of C4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.33% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($2.91) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About C4 Therapeutics (NASDAQ:CCCC) StockC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Stock News HeadlinesMay 30, 2023 | msn.comEvercore ISI Group Maintains C4 Therapeutics (CCCC) Outperform RecommendationMay 30, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for C4 TherapeuticsMay 31, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowMay 30, 2023 | tmcnet.comC4 Therapeutics and Betta Pharmaceuticals Announce Exclusive LicensingMay 30, 2023 | finance.yahoo.comC4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLCMay 30, 2023 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) PT Lowered to $10.00May 28, 2023 | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.83 Average PT from AnalystsMay 14, 2023 | finance.yahoo.comBroker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging HigherMay 31, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!May 12, 2023 | msn.comMorgan Stanley Maintains C4 Therapeutics (CCCC) Underweight RecommendationMay 10, 2023 | americanbankingnews.comHC Wainwright Comments on C4 Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CCCC)May 9, 2023 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) Price Target Cut to $25.00 by Analysts at HC WainwrightMay 9, 2023 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) and Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head AnalysisMay 8, 2023 | msn.comHC Wainwright & Co. Maintains C4 Therapeutics (CCCC) Buy RecommendationMay 8, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for C4 Therapeutics (CCCC)May 8, 2023 | markets.businessinsider.comExpert Ratings for C4 TherapeuticsMay 5, 2023 | markets.businessinsider.comC4 Therapeutics (CCCC) Receives a Buy from SVB SecuritiesMay 5, 2023 | msn.comRecap: C4 Therapeutics Q1 EarningsMay 4, 2023 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsMay 4, 2023 | finance.yahoo.comC4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsMay 3, 2023 | americanbankingnews.comAnalysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $11.86April 19, 2023 | finance.yahoo.comC4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysApril 12, 2023 | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Hold" from BrokeragesApril 11, 2023 | finance.yahoo.comDown -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)April 10, 2023 | americanbankingnews.comBrokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $14.33March 31, 2023 | americanbankingnews.comBank of America Trims C4 Therapeutics (NASDAQ:CCCC) Target Price to $5.00March 23, 2023 | finance.yahoo.comInsiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in valueSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Company Calendar Last Earnings11/10/2021Today5/31/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.86 High Stock Price Forecast$25.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+190.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-128,180,000.00 Net Margins-482.83% Pretax Margin-482.83% Return on Equity-43.26% Return on Assets-29.50% Debt Debt-to-Equity Ratio0.03 Current Ratio7.07 Quick Ratio7.07 Sales & Book Value Annual Sales$27.20 million Price / Sales6.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book0.63Miscellaneous Outstanding Shares49,064,000Free Float42,112,000Market Cap$166.33 million OptionableNot Optionable Beta2.11 Key ExecutivesMr. Andrew J. Hirsch (Age 52)CEO, Pres & Director Comp: $952.2kDr. Kenneth C. Anderson M.D. (Age 72)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $35kMs. Lauren A. WhiteChief Financial OfficerDr. Stewart Fisher (Age 56)Chief Scientific Officer Comp: $694.7kMs. Jolie M. Siegel J.D. (Age 46)Chief Legal Officer Comp: $610.4kDr. Adam S. Crystal M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $701.7kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsSr. VP of Communications & Investor RelationsKristina ZambourasDirector of HRMs. Kelly SchickChief People OfficerMore ExecutivesKey CompetitorsVaxartNASDAQ:VXRTAdaptimmune TherapeuticsNASDAQ:ADAPInvivydNASDAQ:IVVDGraphite BioNASDAQ:GRPHGritstone bioNASDAQ:GRTSView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 41,487 shares on 5/22/2023Ownership: 0.163%JPMorgan Chase & Co.Sold 66,619 shares on 5/18/2023Ownership: 0.069%New York State Common Retirement FundSold 20,738 shares on 5/18/2023Ownership: 0.016%Geode Capital Management LLCBought 43,486 shares on 5/16/2023Ownership: 1.714%Susquehanna Fundamental Investments LLCSold 14,924 shares on 5/16/2023Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions CCCC Stock - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year price targets for C4 Therapeutics' shares. Their CCCC share price forecasts range from $5.00 to $25.00. On average, they anticipate the company's stock price to reach $9.86 in the next twelve months. This suggests a possible upside of 190.8% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2023? C4 Therapeutics' stock was trading at $5.90 on January 1st, 2023. Since then, CCCC shares have decreased by 42.5% and is now trading at $3.39. View the best growth stocks for 2023 here. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The business earned $8.50 million during the quarter, compared to analyst estimates of $7.28 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 43.26% and a negative net margin of 482.83%. What ETFs hold C4 Therapeutics' stock? ETFs with the largest weight of C4 Therapeutics (NASDAQ:CCCC) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Harbor Disruptive Innovation ETF (INNO). When did C4 Therapeutics IPO? (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. What is C4 Therapeutics' stock symbol? C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC." Who are C4 Therapeutics' major shareholders? C4 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (13.01%), Wasatch Advisors LP (11.65%), BlackRock Inc. (7.53%), Price T Rowe Associates Inc. MD (5.86%), Geode Capital Management LLC (1.71%) and State Street Corp (1.58%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Marc A Cohen, Stewart Fisher, Utpal Koppikar and William Mckee. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is C4 Therapeutics' stock price today? One share of CCCC stock can currently be purchased for approximately $3.39. How much money does C4 Therapeutics make? C4 Therapeutics (NASDAQ:CCCC) has a market capitalization of $166.33 million and generates $27.20 million in revenue each year. The company earns $-128,180,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. How many employees does C4 Therapeutics have? The company employs 121 workers across the globe. How can I contact C4 Therapeutics? The official website for the company is www.c4therapeutics.com. The company can be reached via phone at 617-231-0700 or via email at jane.urheim@sternir.com. This page (NASDAQ:CCCC) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.